Inlyta (Axitinib) is one of the most advanced targeted therapies used for the treatment of advanced renal cell carcinoma (RCC). It works by blocking tumor blood vessel growth, helping slow cancer progression.
What is Inlyta?
Inlyta belongs to the class of tyrosine kinase inhibitors (TKIs). It targets VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3), which are essential for tumor angiogenesis. Inlyta is commonly used after failure of previous treatments such as Sunitinib or Pazopanib.
Indications:
- Advanced renal cell carcinoma (RCC).
- Patients who have failed prior systemic therapy.
- Often used in combination with immunotherapies like Pembrolizumab or Avelumab.
Administration:
- Inlyta is taken orally twice daily.
- Can be taken with or without food.
- Tablets must be swallowed whole.
- Dose adjustments may be required based on tolerance.
Common Side Effects:
- High blood pressure.
- Loss of appetite and weight loss.
- Diarrhea or nausea.
- Fatigue.
- Swelling of hands or feet.
- Liver function changes.
Serious but rare side effects include:
- Bleeding events.
- Blood clots.
- Heart complications.
Regular monitoring is required while on Inlyta.
Availability and Price in Egypt:
Inlyta in Egypt is available in oncology hospitals and selected pharmacies. It is considered an expensive medication, typically accessed through insurance or special financial assistance programs.
Conclusion:
Inlyta (Axitinib) is a powerful targeted therapy for advanced kidney cancer, offering improved disease control and patient outcomes. Although costly, its clinical benefits make it an essential option for eligible patients.
